医疗保险受益者中伴有与不伴有阿尔茨海默病/相关痴呆的骨质疏松症药物使用全国趋势
本研究基于2016至2018年无HMO的医疗保险A/B/D部分、年龄≥67岁的骨质疏松症受益者,评估2018年骨质疏松症药物使用情况。伴有阿尔茨海默病/相关痴呆(ADRD)者骨质疏松症药物使用率为38.6%,不伴有ADRD者为52.7%;校正后ADRD与使用骨质疏松症药物的OR为0.85(95%CI:0.83-0.87)。疗养院居民使用骨质疏松症药物的OR为0.61(95%CI:0.58-0.64),ADRD与年龄、ADRD与疗养院居民身份存在显著交互作用。
要点
- 伴有ADRD的骨质疏松症患者骨质疏松症药物使用率为38.6%,不伴有ADRD者为52.7%。
- 校正后ADRD与使用骨质疏松症药物的OR为0.85(95%CI:0.83-0.87)。
- 疗养院居民使用骨质疏松症药物的OR为0.61(95%CI:0.58-0.64),ADRD与疗养院居民身份存在显著交互作用。
核心结论
- 伴有ADRD的患者接受骨质疏松症药物的比例低于不伴有ADRD者。
- 需要在不同ADRD严重程度、患者偏好、剩余预期寿命和骨质疏松症药物获益时间的背景下,进一步研究何时处方或停用骨质疏松症药物。
研究设计与样本
- 研究纳入2016至2018年无HMO、年龄≥67岁且有骨质疏松症的医疗保险A/B/D部分受益者。
- 样本包括47,871例伴有骨质疏松症和ADRD者与201,840例伴有骨质疏松症但不伴有ADRD者。
- 结局为2018年接受骨质疏松症药物;采用多因素logistic回归评估ADRD与骨质疏松症药物处方之间的关联,并校正年龄、性别、种族、地区、医疗保险资格、双重医疗补助资格、慢性病、就诊/住院次数和疗养院居民身份。
- 检验了年龄与ADRD、疗养院居民身份与ADRD的交互作用。
主要发现
- 伴有ADRD患者骨质疏松症药物使用率为38.6%,不伴有ADRD者为52.7%。
- 校正人口学特征、慢性病和既往住院/就诊次数后,ADRD相对于非ADRD使用骨质疏松症药物的OR为0.85(95%CI:0.83-0.87)。
- 疗养院居民使用骨质疏松症药物的OR为0.61(95%CI:0.58-0.64)。
- ADRD与年龄、ADRD与疗养院居民身份存在显著交互作用。
- ADRD相关骨质疏松症药物使用OR在社区居住老年人中为0.88(95%CI:0.86-0.90),在疗养院居民中为0.66(95%CI:0.64-0.69)。
局限性
- 需要在不同ADRD严重程度、患者偏好、剩余预期寿命和骨质疏松症药物获益时间的背景下,进一步研究何时处方或停用骨质疏松症药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoporotic fractures are a leading cause of disability and premature death in the elderly. Patients with Alzheimer's and related dementia (ADRD) have high rates of osteoporosis (OP) and substantial risk of osteoporotic fractures. Yet research is sparse on trends and predictors of OP medication use in ADRD. METHODS: Medicare beneficiaries with OP aged ≥ 67 years have Medicare parts A/B/D without HMO from 2016 to 2018. Our outcome was receipt of OP medications in 2018. A multivariable logistic regression assessed association between ADRD and OP drug prescribing, adjusted for age, sex, race, region, Medicare entitlement, dual Medicaid eligibility, chronic conditions, number of provider visits/hospitalizations, and nursing home (NH) resident status. Age/ADRD and NH residency/ADRD interactions were tested. RESULTS: Our sample consisted of 47,871 people with OP and ADRD and 201,840 with OP without ADRD. OP drug use was 38.6% in ADRD patients vs. 52.7% in non-ADRD. After adjustment for demographics, chronic conditions, and previous hospitalizations/physician visits, the OR for OP drug in ADRD vs. non-ADRD was 0.85 (95% CI: 0.83-0.87). NH residents had lower odds for OP medication (OR: 0.61, 95% CI: 0.58-0.64). There were significant interactions between ADRD and age, and between ADRD and NH residency. The OR for OP drug use associated with ADRD was 0.88 (95% CI: 0.86-0.90) among community-dwelling elders and 0.66 (95% CI: 0.64-0.69) among NH residents. CONCLUSIONS: ADRD patients received OP drugs at a lower rate than their non-ADRD counterparts. More research is needed on when to prescribe or deprescribe OP drugs in the context of different ADRD severity, patient preferences, remaining life expectancy, and time-to-benefit from OP drugs.
引用
- Armstrong P, Kuo YF, Cram P, et al. National trends in osteoporosis medication use among Medicare beneficiaries with and without Alzheimer's disease/related dementias. Osteoporos Int. 2023. PMID: 36729144. doi:10.1007/s00198-023-06680-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。